JPH0548228B2 - - Google Patents
Info
- Publication number
- JPH0548228B2 JPH0548228B2 JP60135224A JP13522485A JPH0548228B2 JP H0548228 B2 JPH0548228 B2 JP H0548228B2 JP 60135224 A JP60135224 A JP 60135224A JP 13522485 A JP13522485 A JP 13522485A JP H0548228 B2 JPH0548228 B2 JP H0548228B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- chlorophenyl
- tetrazole
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 239000000460 chlorine Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 102000014654 Aromatase Human genes 0.000 abstract description 7
- 108010078554 Aromatase Proteins 0.000 abstract description 7
- 229940011871 estrogen Drugs 0.000 abstract description 7
- 239000000262 estrogen Substances 0.000 abstract description 7
- -1 tetrazol-2-yl compounds Chemical class 0.000 abstract description 7
- 230000001419 dependent effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 abstract 1
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229960005471 androstenedione Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 210000001589 microsome Anatomy 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- PRRSYFZERBDOEZ-UHFFFAOYSA-N 1-[bis(4-chlorophenyl)methyl]triazole Chemical compound C1=CC(Cl)=CC=C1C(N1N=NC=C1)C1=CC=C(Cl)C=C1 PRRSYFZERBDOEZ-UHFFFAOYSA-N 0.000 description 3
- DIKFTTPTTFVNPW-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]tetrazole Chemical compound C1=CC(Cl)=CC=C1C(N1N=NC=N1)C1=CC=C(Cl)C=C1 DIKFTTPTTFVNPW-UHFFFAOYSA-N 0.000 description 3
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 3
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 3
- 229940046836 anti-estrogen Drugs 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 239000003886 aromatase inhibitor Substances 0.000 description 3
- 229940046844 aromatase inhibitors Drugs 0.000 description 3
- 238000005899 aromatization reaction Methods 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LKBJQRZQDCMBBJ-UHFFFAOYSA-N 1-chloro-4-[chloro-(4-chlorophenyl)methyl]benzene Chemical compound C=1C=C(Cl)C=CC=1C(Cl)C1=CC=C(Cl)C=C1 LKBJQRZQDCMBBJ-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NGLDVEWVZKDNOL-UHFFFAOYSA-N 1-[(4-methoxyphenyl)-(4-methylphenyl)methyl]triazole Chemical compound C1=CC(OC)=CC=C1C(N1N=NC=C1)C1=CC=C(C)C=C1 NGLDVEWVZKDNOL-UHFFFAOYSA-N 0.000 description 1
- AXGLFYOIVQGBRN-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)-1-phenylethyl]triazole Chemical compound C=1C=C(Cl)C=CC=1C(N1N=NC=C1)(C)C1=CC=CC=C1 AXGLFYOIVQGBRN-UHFFFAOYSA-N 0.000 description 1
- GAKWPZYLXDZXKP-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]triazole Chemical compound C1=CC(F)=CC=C1C(N1N=NC=C1)C1=CC=C(F)C=C1 GAKWPZYLXDZXKP-UHFFFAOYSA-N 0.000 description 1
- FNOTUCMOXQMXKW-UHFFFAOYSA-N 1-benzhydryltriazole Chemical compound N1=NC=CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 FNOTUCMOXQMXKW-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical class C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 1
- KDNXOHSNZXVMTM-UHFFFAOYSA-N 3-[triazol-1-yl-[4-(trifluoromethyl)phenyl]methyl]pyridine Chemical compound C1=CC(C(F)(F)F)=CC=C1C(N1N=NC=C1)C1=CC=CN=C1 KDNXOHSNZXVMTM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PHUYGURFBULKPA-UHFFFAOYSA-N 4,4'-dichlorobenzhydrol Chemical compound C=1C=C(Cl)C=CC=1C(O)C1=CC=C(Cl)C=C1 PHUYGURFBULKPA-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010011631 Equine Gonadotropins Proteins 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000007980 azole derivatives Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000012587 nuclear overhauser effect experiment Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
ç£æ¥äžã®å©çšåé
æ¬çºæã¯åŒïŒ
ïŒåŒäžãã¯ããªãžã«ãŸãã¯
ãåŒã
R1ãR2ãR3ããã³R4ã¯åã
ç¬ç«ããŠæ°ŽçŽ ãã¡ã
ã«ãããªãã«ãªãã¡ãã«ãã¡ããã·ããŸãã¯ãã
ã²ã³ïŒïŒ¥ããã³ïŒ±ã¯åã ç¬ç«ããŠïŒ®ãŸãã¯CHã
è¡šãããã ããããã³ïŒ±ãåæã«ïŒ®ãè¡šãããš
ã¯ãªããïŒ ã§ç€ºãããããªã¢ãŸãŒã«ããã³ããã©ãŸãŒã«åå
ç©ããŸãã¯ãã®å¡©ã«é¢ãããã®ã§ããã åŸæ¥æè¡ ãšã¹ããã²ã³é¡ã¯ã¢ã³ããã²ã³ç³»ã¹ããã€ãé¡
ããåæãããããšã¹ããã²ã³ã®çåæéçšã«ã
ããŠã¯ãè³éŠæåãå¿ é ã®å·¥çšã§ãããäžè¬ã«ã
ãã®ã¢ããã¿ãŒãŒïŒè³éŠæåïŒé µçŽ ãå¹æçã«é»
害ãåŸããªãã°ããšã¹ããã²ã³äŸåæ§çŸæ£ã®æ²»ç
ã«æçšã§ããããšèããããŠããïŒã«ã³ãµãŒã»ãª
ãµãŒãïŒCancer ResearchïŒ42å·»ãå¢åãïŒïŒ
3261SïŒ1982ïŒåç §ïŒã ã¢ããã¿ãŒãŒé»å®³å€ã§æ²»çãåŸããšã¹ããã²ã³
äŸåæ§çŸæ£ã«å¹Ÿã€ãã®ãã®ãããããã®æ§ãªçŸæ£
ã«ã¯ãä¹³ãããåå®®å èçãå€å¢èæ§åµå·£çŸæ£ã
è¯æ§ä¹³æ¿çãããã³åå®®å èããçãå«ãŸããã
æãšã¹ããã²ã³å€ã®ä¹³ããæ²»çã«ãããæçšæ§ã¯
æ¢ã«ç«èšŒãããŠããïŒããªãã€ãã·ãŠã»ãžã€ãŒã
ã«ã»ãªãã»ã«ã³ãµãŒïŒBr.J.CancerïŒ25 270
ïŒ1971ïŒåç §ãïŒïŒã€ã®æ¢ç¥ã®ã¢ããã¿ãŒãŒé»å®³
å€ããã¹ãã©ã¯ãã³ããã³ã¢ããã°ã«ãããã
ã¯ãä¹³ããã®æ²»çã«æå¹ã§ããããšãããã€ãŠã
ãïŒã«ã³ãµãŒã»ãªãµãŒãïŒåäžïŒåç §ïŒã åå®®å èçã¯ãåå®®å èã®ç°åžžãªå¢æ®ãç¹åŸŽãš
ãããåå®®å èã®å¢æ®ã¯ãšã¹ãã©ãžãªãŒã«äŸåæ§
ã§ãããåŸã€ãŠããšã¹ããã²ã³çæé»å®³å€ã«ãã€
ãŠãã®çŸæ£ã®é²è¡ãåæ¢ãããããšãã§ããã¯ã
ã§ããã è¯æ§ä¹³æ¿çã¯ããã°ãã°ç·ç¶å¢èæ§ä¹³æ¿çãšã
åŒã°ããçŸæ£ã§ãããåµå·£ã¹ããã€ããã«ã¢ã³äŸ
åæ§ãšæãããïŒã«ã³ãµãŒïŒCancerïŒ49 2534
ïŒ1982ïŒåç §ïŒããã®çŸæ£ã«å¯ŸããŠã¢ããã¿ãŒãŒé»
害å€ã®äœ¿çšãè©Šã¿ãäŸã¯ãªãããæãšã¹ããã²ã³
é¡ã¯æå¹ã§ãããšæãããïŒãªãã¹ãããªã¯ã¹ã»
ã®ãã³ããžã€ïŒObstet.Gynecol.ïŒ5480ïŒ1979ïŒå
ç §ïŒã å€å¢èæ§åµå·£çŸæ£ã¯ã女æ§ã«ãããäžåŠçã®æ
ãäžè¬çãªåå ã®ïŒã€ã§ããããã®çŸæ£ã®ç å
ã¯ãã¹ããã€ãã®ä»£è¬ç°åžžã«ãããããã該çŸæ£
ã®äž»èŠãªæ²»çå€ã¯æãšã¹ããã²ã³å€ãã¯ããããš
ã³ã§ããïŒã¯ãªãã«ã«ã»ãšã³ãã¯ãªãããžã€
ïŒClin.Endocrinol.ïŒ12 177ïŒ1980ïŒåç §ïŒã çºæã®æ§æããã³ç®ç æ¬çºæã«ãããŠå¥œãŸããååç©ã¯ãåŒäžïŒ(a)
R1ãããã²ã³ãç¹ã«åŒçŽ ãŸãã¯å¡©çŽ ããããã¯
ããªãã«ãªãã¡ãã«ã§ããã(b)ãããšãã«
ïŒR3ããã³R4ã®äž¡æ¹ãæ°ŽçŽ ã§ããïŒãŸãã¯çœ®æã
ãšãã«ãç¹ã«ãR3ãããã²ã³ïŒäžã§ãå¡©çŽ ãŸã
ã¯åŒçŽ ïŒãããã¯ããªãã«ãªãã¡ãã«ã§ããåå
ç©ã§ãããç¹ã«å¥œãŸããã®ã¯ãåŒäžïŒ(a)R1ãã
ã³R2ãå ±ã«å¡©çŽ ãç¹ã«ïŒïŒïŒâãžã¯ããã§ããã
ãé眮æããšãã«ã§ãããããŸãã¯(b)ãã¢ã
眮æããšãã«ãR1ããã³R3ãåã ç¬ç«ããŠå¡©çŽ
ãŸãã¯åŒçŽ ããããŠR2ããã³R4ãæ°ŽçŽ ã§ããå
åç©ã§ããã æã奜ãŸããæ¬çºæååç©ã¯ïŒâããã¹ïŒïŒâ
ã¯ããããšãã«ïŒã¡ãã«ãâ1HâïŒïŒïŒïŒïŒâã
ãªã¢ãŸãŒã«ããã³ïŒâããã¹ïŒïŒâã¯ããããšã
ã«ïŒã¡ãã«ãâ2Hâããã©ãŸãŒã«ããã³ãããã®
è¬åŠçã«èš±å®¹ãåŸãå¡©ã§ããã æ¬æ现æžäžãâããã²ã³âãšããèªå¥ã¯ãåŒçŽ ã
å¡©çŽ ãèçŽ ããã³æ²çŽ ãæå³ãããâããªãžã«â
ãšããèªå¥ã¯ïŒâãïŒâãŸãã¯ç¹ã«ïŒâããªãžã«
ãæå³ããã åœæ¥è ã«ã¯ç解ãããããšã ããäžèšã®åŒã§ç€º
ãããååç©ã«ã¯äžæŽççŽ ååãååšãåŸããæ¬
çºæã¯ç¹å®ã®ç°æ§äœã«éå®ããããã®ã§ã¯æ±ºããŠ
ãªãã該ååç©ã®åã ã®ãšãã³ããªããŒããã³ã©
ã»ãäœãå å«ãããã®ã§ããã ãŸããããã³ïŒ±ã®å ãäžæ¹ãã§ä»æ¹ãCH
ã®ãšãã¯ãäžèšã®åŒã§ç€ºãããååç©ã¯ïŒâãŸã
ã¯ïŒâ眮æããã©ãŸãŒã«ãšãªãããããã®ïŒã€ã®
åã®ããã©ãŸãŒã«ååç©ã¯å¥ã ã®é ã§ç¹èš±è«æ±ã
ããŠãããã補é æ¹æ³ã«ãã€ãŠã¯ããããã¯äžç·
ã«çæãããåŸã€ãŠãæ¬çºæã¯ïŒâããã³ïŒâ眮
æããã©ãŸãŒã«ã®åã ã䞊ã³ã«ãããã®æ··åç©ã
å å«ãããã®ã§ãããæ¬æ现æžäžãäžèšã®æ··åç©
ããïŒ(2)â眮æããã©ãŸãŒã«ãšè¡šãã åèšã®åŒã§ç€ºãããå¡©åºã®è¬åŠçã«èš±å®¹ãåŸã
é žä»å å¡©ã¯ãä»å å¡©ã圢æããã®ã«å åãªé žæ§åºŠ
ã®é žãçšããŠåŸãããšãã§ããããã®æ§ãªé žã«
ã¯ãå¡©é žãèåæ°ŽçŽ é žãæ²åæ°ŽçŽ é žãç¡«é žããã
é žãä¿®é žãã¡ã¿ã³ã¹ã«ãã³é žããã³ãŒã³ã¹ã«ãã³
é žãïœâãã«ãšã³ã¹ã«ãã³é žããã³ãã¬ã€ã³é žç
ã®ç¡æ©ããã³ææ©é žãå«ãŸãããå¡©ã®åœ¢æã«å¥œãŸ
ããã®ã¯ç¡æ©é žãç¹ã«å¡©é žã§ããã åŒã®ååç©ã®è£œé æ¹æ³ æ¬çºæååç©ã¯æ°çš®é¡ã®æ¹æ³ã®å ãä»»æã®æ¹æ³
ã§è£œé ããããšãã§ãããæ¬çºæååç©ã®å¥œãŸã
ã補é æ¹æ³ã¯ã以äžã®åå¿åŒïŒ ãåŒäžãã¯ããã²ã³ïŒå¥œãŸããã¯å¡©çŽ ãŸãã¯è
çŽ ïŒãããã¯ããããã·ãè¡šãã ã§ç€ºããããéåžžãååç©ãšãšããã¢ã«ã«ãª
éå±ã®æ°ŽçŽ åç©ãæ°Žé žåç©ãã¢ã«ã³ãã·ãåå
ç©ããŸãã¯çé žå¡©ã®åŠãå¡©åºã®ååšäžã奜ãŸãã
ã¯ãžãªããµã³ããŸãã¯ãžã¡ãã«ãã«ã ã¢ããã®åŠ
ããžã¢ã«ãã«ãã«ã ã¢ããã®æ§ãªé«æ²žç¹ã®éâå
å¿æ§æº¶åªäžã§åå¿ããããäžè¬ã«ãã¢ãŸãŒã«èªå°
äœããéåžžãå ããªéå°éããïŒåéå°éã®ç¯
å²å ã§ãéå°ã«çšãããæ®éãåå¿ã¯ãäžæŽ»æ§é°
å²æ°äžãçŽ20âããåå¿æ··åç©ã®æ²žç¹ãŸã§ã®æž©åºŠ
ç¯å²ã§è¡ããæ°ŽçŽ åãããªãŠã ãšãžã¡ãã«ãã«ã
ã¢ããã䜿çšãã枩床çŽ80°ã100âã®å¥œãŸããå
å¿æ¡ä»¶ã®äžã§ã¯ãåå¿ã¯ãéåžžãçŽïŒã24æéã®
å ã«çµäºãããäžéäœããã³ã¯ãåžè²©åãå ¥
æãåŸãããæç®ã«èšèŒãããŠããããããã¯åœ
æ¥è åšç¥ã®æ¹æ³ã§å®¹æã«è£œé ããããšãã§ããã 以äžã«å®æœäŸãæããæ¬çºæãæŽã«è©³ãã説æ
ããããããã®å®æœäŸã¯åãªãäŸç€ºã«ããããåŠ
äœãªãæå³ã«ãããŠãæ¬çºæã®ç¯å²ãå¶éããã
ã®ã§ã¯ãªãã å®æœäŸ ïŒ ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ
2Hâããã©ãŸãŒã«  ïŒïŒ4â²âãžã¯ãããã³ãºãããªã«ã»ã¯ããªã
ã®è£œé ïŒïŒ4â²âãžã¯ãããã³ãºããããŒã«75ïœã«å¡©
åããªãã«42ïœãåŸã ã«å ãããæ·»å çµäºåŸã
åå¿æ··åç©ãèžæ°æµŽäžã§ïŒæéå ç±ãããéå°
éã®å¡©åããªãã«ãæžå§äžã«é€å»ãããåå¡©å
ççŽ 100mlãå ãã溶åªãçå»ããããã®åå¡©
åççŽ ã«ããåŠçãç¹°è¿ããŠè¡ã€ãåŸãæ²¹ç¶ã®
æ®çç©ãç³æ²¹ãšãŒãã«ããçµæ¶åãããå¯é¡ã®
äžéäœ65.3ïœãåŸããmpïŒ63âã  ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ
2Hâããã©ãŸãŒã«ã®è£œé ããã©ãŸãŒã«3.12ïœãçé žã«ãªãŠã 26.2ïœã
ãã³äžã§åŸãïŒïŒ4â²âãžã¯ãããã³ãºãããª
ã«ã»ã¯ããªã10ïœã®æ··åç©ãçªçŽ é°å²æ°äžããž
ã¡ãã«ãã«ã ã¢ãã150mläžã§85ã90âã«ãã
ãŠ2.5æéãæŽã«60ã65âã«ãããŠäžå€å ç±ã
ãããã®åå¿æ··åç©ãå¡©åãããªãŠã 飜å溶液
ïŒäžã«æ³šå ããåŸãé ¢é žãšãã«200mlã§ïŒå
æœåºãããææ©æœåºæ¶²ãåãããŠå¡©åãããªãŠ
ã 飜å溶液ã§ïŒåæŽæµããç¡«é žãã°ãã·ãŠã ã§
也ç¥ããåŸãèžçºä¹ŸåºããŠæ·¡é»è²ã®æ²¹ç¶ç²çæ
ç©12.1ïœãåŸãããã®æ®çç©ãé«é液äœã¯ãã
ãã°ã©ãã€ãŒã§ç²Ÿè£œãããã¡ã¿ããŒã«ããåçµ
æ¶ããïŒâããã©ãŸãŒã«èªå°äœã®çœè²çµæ¶1.1
ïœãäžæ¬¡çæç©ãšããŠååãããmpïŒ91ã92
âããã®çæç©ããã¹ã¹ãã¯ãã«åæã«ããã
劥åœãªååéãæããŠããããšïŒM+ïŒ305ïŒã
確èªãããšå ±ã«ã13Cããã³1HNMR NOEå®éš
ã«ããããã®äžæ¬¡çæç©ããïŒâããã¹ïŒïŒâ
ã¯ããããšãã«ïŒã¡ãã«ãâ2Hâããã©ãŸãŒã«
ã§ããããšã確èªããã ïŒC14H10Cl2N4ïŒå çŽ åæ    èšç®å€ïŒ55.10 3.30 18.36 å®æž¬å€ïŒ55.05 3.45 18.18 å®æœäŸ ïŒ ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ
1HâïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« å®æœäŸ1Bã®äžè¬çãªæ¹æ³ã«åŸããïŒïŒïŒïŒïŒ
âããªã¢ãŸãŒã«5.0ïœã®ãžã¡ãã«ãã«ã ã¢ãã100
mläžæº¶æ¶²ãããŸãæ°ŽçŽ åãããªãŠã ïŒ60ïŒ é±æ²¹äž
溶液ãšããŠïŒ1.44ïœã次ãã§ïŒïŒ4â²âãžã¯ããã
ã³ãºãããªã«ã»ã¯ããªã5.0ïœã§åŠçããããã®
åå¿æ··åç©ãçŽ25âã§äžå€æ¹æããåŸãèžæ°æµŽäž
ã§äžå€å ç±ãããäžé£ã®å®éšçµäºåŸãæ®çç©ãã¯
ãããã°ã©ãã€ãŒã«ããããšãããç®çç©è³ªã§ãª
ãïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ
2HâïŒïŒïŒïŒïŒâããªã¢ãŸãŒã«2.4ïœãšãç®çç©
質ã§ããè¡šé¡ã®ååç©3.1ïœãšãåŸããmpïŒ124
ã125âã ïŒC15H11Cl2N3ïŒå çŽ åæ    èšç®å€ïŒ59.23 3.65 13.81 å®æž¬å€ïŒ59.45 3.86 13.81 æ¬çºæååç©çŸ€ã¯ãã¢ããã¿ãŒãŒé µçŽ é»å®³æŽ»æ§
ãæããŠãããåŸã€ãŠãåºä¹³é¡åç©ã«ãããä¹³ã
ãçã®ãšã¹ããã²ã³äŸåæ§çŸæ£ã«å¯Ÿããäºé²ç
ãªããŸãã¯æ²»çãç®çãšããåŠçã«äœ¿çšã§ããã
æ¬çºæååç©ã®ã¢ããã¿ãŒãŒé»å®³æŽ»æ§ãã
Brodieãã®ãåé¢ããã©ããã®åµå·£ãã¯ããŸãŒ
ã ãçšããæ¹æ³ïŒãžã€ãŒãã«ã»ãªãã»ã¹ããã€
ãã»ãã€ãªã±ãã¹ããªã€ïŒJ.Steroid Biochem.ïŒ
ïŒ 787ïŒ1976ïŒïŒã®æ¹è¯æ³ã«ãã蚌æããããã®
å®éšã·ã¹ãã ã«ãããŠã¯ãåŠéŠ¬ã®è¡æž ãŽãããã
ãã³ã§åŠçããã©ããããåµå·£ãã¯ããŸãŒã ãå
é¢ããã0.1ÎŒïœã®ïŒâã¢ã³ããã¹ãã³âïŒïŒ17â
ãžãªã³ã100000dpmã®ïŒïŒïŒïŒ»3Hâã¢ã³ããã¹
ãã³ãžãªã³ãäžèšã®ãã¯ããŸãŒã ããã³
NADPHçæç³»ãå«æããåå¿å®¹åšïŒãã€ã¢ã«ïŒ
ã«è¢«æ€ååç©ãå ãããè©Šéšãããã®é»å®³å€ã®æ¿
床ç¯å²ã¯0.005ã10ÎŒïœã§ããããã®æž¬å®æ³ã«ãã
ã°ãã¢ã³ããã¹ãã³ãžãªã³ã®è³éŠæåã«ãã€ãŠ
3HâH2Oãçæããã®ã§ãããããè©Šæãã¯
ãããã«ã ã§æœåºããããšã«ãã€ãŠåé¢ããåŸã
ããæ°Žå±€ã掻æ§çåŠçããŠéé¢ã®ã¹ããã€ããé€
ããè©Šæã液äœã·ã³ãã¬ãŒã·ãšã³åå åšã«å ¥ããŠ
èšæ°ãããã®çµæããé»å®³å€ãå ããã«ã€ã³ããŠ
ããŒãããŠåŸãå¯Ÿç §è©Šæã«ãããçµæãšæ¯èŒãã
ããšã«ãããé»å®³çïŒïŒ ïŒãæ±ãããå¹åã¯ãåº
質ïŒã¢ã³ããã¹ãã³ãžãªã³ïŒã®æ¿åºŠã0.1ÎŒïœã®å Ž
åã«ãããŠãé µçŽ æŽ»æ§ã50ïŒ é»å®³ããã®ã«å¿ èŠãª
é»å®³å€ã®æ¿åºŠïŒÎŒïœïŒã«åºã¥ããŠè¡šãã
ïŒEC50ïŒãåèšã®åŒã§ç€ºãããããã€ãã®ååç©
ã®EC50å€ãè¡šïŒã«ç€ºãã è¡šïŒ ã©ããåµå·£ãã¯ããŸãŒã ã¢ãã»ã€ã«ãããã¢ãã
ã¿ãŒãŒé»å®³äœçš â»è¢«æ€ååç© EC50 ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ1H
âïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« ïŒ0.05 ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ2H
âããã©ãŸãŒã« 0.15 â» åºè³ªæ¿åºŠ0.1ÎŒïœã®å Žåã«ã¢ããã¿ãŒãŒæŽ»æ§
ã50ïŒ é»å®³ããã®ã«å¿ èŠãªè¢«æ€ååç©ã®æ¿åºŠ
ïŒåäœÎŒïœïŒã æ¬çºæååç©ã¯ãçµå£ãç®äžãçèå ãéè
å ãçµç®ããã³çµçŽè žãå«ãçš®ã ã®çµè·¯ã§æäžã
ãããšãã§ãããæ¬çºæååç©ã¯ãäžè¬ã«å»è¬çµ
æç©ã®åœ¢ã§çšããããããããã®çµæç©ã¯è£œè¬æ¥
è åšç¥ã®æ¹æ³ã§è£œé ãããå°ãªããšãïŒåã®åèš
ã®åŒã§ç€ºããã掻æ§ååç©ãå«æããŠããã åŸã€ãŠæ¬çºæã¯ã掻æ§æåã§ããåèšåŒã®åå
ç©ãšãè¬åŠçã«èš±å®¹ãåŸãåŠäœãšãå«æããå»è¬
çµæç©ãå å«ãããã®ã§ããããã®çµæç©ã調補
ããã«ã¯ãéåžžã掻æ§æåãåŠäœãšæ··åãããåŠ
äœã§åžéãããããŸãã¯ãã«ãã»ã«ããµã·ãšãçŽ
çã®å®¹åšã®åœ¢ç¶ãæããä¿æäœå ã«å°å ¥ããã åŠäœãåžéå€ã§ããå Žåãããã¯æŽ»æ§ç©è³ªã«å¯Ÿ
ãã賊圢è¬ãè£åœ¢è¬ãŸãã¯åªè³ªãšããŠäœçšããåº
åç©è³ªãååºåç©è³ªãŸãã¯æ¶²äœç©è³ªã§ãããäŸã
ã°ãæ¬çºæã®çµæç©ã¯ãé å€ãäžžå€ãç²å€ãããŒ
ã³ãžããµã·ãšå€ãã«ã·ãšå€ããšãªãã·ã«å€ãä¹³
å€ã液å€ãã·ãããå€ãæžæ¿å€ãåŽé§å€ïŒåºäœãš
ããŠããŸãã¯æ¶²äœåªè³ªã«å ¥ããŠïŒãè»èïŒäŸãã°
掻æ§ååç©ãæé«10ééïŒ å«æãããã®ïŒããŒã©
ãã³è»ã«ãã»ã«ããã³ãŒã©ãã³ç¡¬ã«ãã»ã«ãå
è¬ãæ» è泚å°çšæ¶²äžŠã³ã«æ» èå è£ ç²å€çã®å€åœ¢ã
ãšãåŸãã é©åœãªåŠäœãè£åœ¢è¬ãŸãã¯åžéå€ã«ã¯ãäŸã
ã°ãä¹³ç³ãããã¹ãããŒã¹ãã·ãŠã¯ããŒã¹ããœã«
ãããŒã«ããã³ãããŒã«ããã³ãã³ãã¢ã«ã·ã¢ãŽ
ã ããªã³é žã«ã«ã·ãŠã ãã¢ã«ã®ããŒãé¡ãã±ã€é ž
ã«ã«ã·ãŠã ã埮çµæ¶ã»ã«ããŒã¹ãããªããã«ãã
ãªãã³ãã»ã«ããŒã¹ããã©ã¬ã«ã³ãããŒã©ãã³ã
ã·ããããã¡ãã«ã»ã«ããŒã¹ããªãã·å®æ¯éŠé žã¡
ãã«ããªãã·å®æ¯éŠé žãããã«ãã¿ã«ã¯ãã¹ãã¢
ãªã³é žãã°ãã·ãŠã ãæ°Žããã³é±æ²¹ãå«ãŸããã
ãŸããæ¬çºæã®å»è¬è£œå€ã«ã¯æ»æ²¢å€ã湿最å€ãä¹³
åå€ããã³æžæ¿å€ãé²è å€ãçå³æãŸãã¯ãã¬ãŒ
ããŒçãæ·»å ããŠããããæ¬çºæã®çµæç©ã¯ãåœ
æ¥è åšç¥ã®æ¹æ³ãçšããŠãæ£è ã«æäžããåŸã«æŽ»
æ§æåãè¿ éã«ãæç¶çã«ãŸãã¯é 延ããŠæŸåºã
ãæ§ã«è£œå€åããããšãã§ããã çµå£æäžã®ç®çã«ã¯ãæ¬çºæååãåŠäœããã³
åžéå€ãšæ··åããŠé å€ã«æé ãããããŒã©ãã³ã«
ãã»ã«ã«å å¡«ããããšãã§ããããããã¯ãŸãã
ãã®æ··åç©ã10ïŒ ãããŠç³æ°Žæº¶æ¶²ãç匵æ§é£å¡©æ°Ž
ããã³æ» èæ°Žçã®æ¶²äœã«æº¶è§£ããéèå æäžããŸ
ãã¯æ³šå°ããŠãããããã®æ§ãªæ§çµµããææã«ã
ãåçµä¹Ÿç¥ããŠæ» èã¢ã³ãã«ã«ä¿åããŠãããçš
ææ» èæ°Žãå ããŠçèå 泚å°ã®ããã®æ³šå°æ¶²ã«å
調補ãåŸãããã«ããŠãããã ãããã®çµæç©ã¯ãæäžå€åœ¢äžã«æŽ»æ§æåãçŽ
ïŒãçŽ500mgãããäžè¬çã«ã¯çŽïŒãçŽ300mgå«æ
ãããæ§ã«ãæäžåäœå€åœ¢ã«è£œå€åããããšã奜
ãŸãããâæäžåäœå€åœ¢âãšããèªå¥ã¯ããã察
象ãŸãã¯ä»ã®åºä¹³åç©ã«å¯ŸããŠé©åãªåäžã®çšé
ãå«ããç©ççã«ç¬ç«ããäžã€ã®æäžåäœã§ãã€
ãŠãææã®æ²»çå¹æãçŸããããšãäºæ³ãããèš
ç®éã®æŽ»æ§æåãšãææã®è£œè¬çšæ äœãšãå«æã
ããã®ãæãã 掻æ§ååç©ã¯åºç¯ãªçšéåã§æå¹ã§ãããäŸã
ã°ïŒæ¥åœããã®æäžéã¯éåžžçŽ0.05ãçŽ300mgïŒ
Kgã®ç¯å²å ãšãªãããããæ人ã«å¯Ÿããæ²»çæã«
ã¯ãçŽ0.1ãçŽ50mgïŒKgãïŒåã§ãŸãã¯åå²æäž
ãããšãããããããªãããå®éã®æäžéã¯ãæ²»
çæ¡ä»¶ãéžã°ããæäžååç©ãåã ã®æ£è ã®å¹Ž
什ãäœéããã³å¿çæ§ãçç¶ã®é節床ã䞊ã³ã«éž
æãããæäžçµè·¯çãå«ãé¢é£äºé ã«ç §ãããŠå»
åž«ã決å®ããã®ã§ãäžèšã®çšéåã決ããŠæ¬çºæ
ã®ç¯å²ãéå®ãããã®ã§ãªããšããããšã¯ç解ã
ããã§ãããã 以äžã«è£œå€ã«é¢ããå®æœäŸãæããæ¬çºæã®å®
æœæ æ§ãæŽã«è©³ãã説æããããããã®è£œå€äŸã¯
åãªãäŸç€ºã«ãããããããªãæå³ã«ãããŠãæ¬
çºæã®ç¯å²ãå¶éãããã®ã§ã¯ãªãããããã®è£œ
å€äžã«ã¯ãåèšã®åŒã§ç€ºãããæ¬çºæã®å»è¬åå
ç©ãã掻æ§æåãšããŠå«æãããŠããã å®æœäŸ ïŒ ä»¥äžã®æåã§ãŒã©ãã³ç¡¬ã«ãã»ã«ã調補ãããæå éïŒmgïŒã«ãã»ã«ïŒ ïŒâããã¹ïŒïŒâãã«ãªãã ãšãã«ïŒã¡ãã«ãâ1Hâ ïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« 250 也ç¥ãã³ãã³ 200 ã¹ãã¢ãªã³é žãã°ãã·ãŠã 10 èš 460 äžèšæåãæ··åãããŒã©ãã³ç¡¬ã«ãã»ã«ã«å 容
é460mgãšããŠå å¡«ããã å®æœäŸ ïŒ è¬ç©20mgãå«æããã«ãã»ã«å€ã以äžã®åŠãã«
ããŠèª¿è£œãããæå éïŒmgïŒã«ãã»ã«ïŒ ïŒ(2)âãïŒïŒâã¯ããã ãšãã«ïŒïŒïŒâãã«ãªãããš ãã«ïŒã¡ãã«ãâ1HïŒ2H ïŒâããã©ãŸãŒã« 20 ãã³ãã³ 89 埮çµæ¶ã»ã«ããŒã¹ 89 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ èš 200 掻æ§æåãã»ã«ããŒã¹ããã³ãã³ããã³ã¹ãã¢
ãªã³é žãã°ãã·ãŠã ãæ··åããNo.45ã¡ãã·ãŠã®ãµ
ããïŒU.S.sieveïŒã«ããã容é200mgã§ãŒã©ãã³
硬ã«ãã»ã«ã«å å¡«ããã å®æœäŸ ïŒ æŽ»æ§æå100mgãå«æããã«ãã»ã«å€ã以äžã®
åŠã調補ãããæå éã«ãã»ã« ïŒâãïŒïŒâããªãã«ãªã ã¡ãã«ããšãã«ïŒïŒïŒâããªãž ã«ïŒã¡ãã«ãâ1HâïŒïŒ ïŒïŒïŒâããªã¢ãŸãŒã« 100mg ããªãªãã·ãšãã¬ã³ãœã« ãã¿ã³ã»ã¢ããªã¬ãšãŒã 50mcg ãã³ãã³æ« 250mg äžèšæåãè¯ãæ··åãã空ã®ãŒã©ãã³ã«ãã»ã«
ã«å å¡«ããã å®æœäŸ ïŒ æŽ»æ§æå10mgãå«æããé å€ã以äžã®æ¹æ³ã§èª¿
補ãããæå éïŒmgïŒé ïŒ ïŒ(2)âãïŒïŒïŒïŒâãžã¯ãã ããšãã«ïŒïŒïŒâã¯ããããšã ã«ïŒã¡ãã«ãâ1HïŒ2HïŒâã ãã©ãŸãŒã« 10 ãã³ãã³ 45 埮çµæ¶ã»ã«ããŒã¹ 35 ããªããã«ãããªãã³ ïŒ10ïŒ æ°Žæº¶æ¶²ãšããŠïŒ ïŒ ã«ã«ããã·ã¡ãã«ã»ãã³ãã³ ã»ãããªãŠã 4.5 ã¹ãã¢ãªã³é žãã°ãã·ãŠã 0.5 ã¿ã«ã¯ ïŒ èš 100 掻æ§æåããã³ãã³ããã³ã»ã«ããŒã¹ãNo.45ã¡
ãã·ãŠïŒU.S.sieveãã¢ã¡ãªã«æšæºãµããïŒã®ãµ
ããã«ãããŠããæ··åããŠãããåŸãããç²æ«ã
ããªããã«ãããªãã³æº¶æ¶²ãšæ··åããåŸãNo.14ã¡
ãã·ãŠïŒU.S.sieveïŒã®ãµããã«ãããããã®æ§
ã«ããŠåŸãããé¡ç²ã50ã60âã§ä¹Ÿç¥ããNo.18ã¡
ãã·ãŠïŒU.S.sieveïŒã®ãµããã«ãããã次ãã§ã
äºãNo.60ã¡ãã·ãŠïŒU.S.sieveïŒã®ãµããã«éã
ãŠãããã«ã«ããã·ã¡ãã«ãã³ãã³ã»ãããªãŠ
ã ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ããã³ã¿ã«ã¯ãã
ã®é¡ç²ã«å ããæ··åããåŸãæé æ©ã«å ¥ããæé
ããå100mgã®é å€ãåŸãã å®æœäŸ ïŒ ä»¥äžã®æåã§é å€ã調補ãããæå éïŒmgïŒé ïŒ ïŒâãïŒâïŒïŒâã¯ããããšã ã«ïŒâïŒâããšãã«ãšãã«ãâ 1HâïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« 250 埮çµæ¶ã»ã«ããŒã¹ 400 溶èäºé žåã±ã€çŽ 10 ã¹ãã¢ãªã³é ž ïŒ èš 665 äžèšæåãæ··åããå665mgã®é å€ã«æé ããã å®æœäŸ ïŒ æŽ»æ§æå25mgãå«æããåè¬ã以äžã®åŠãã«èª¿
補ããã éïŒmgïŒåè¬ïŒ ïŒâãïŒïŒâã¡ãã«ããšãã«ïŒ ïŒïŒâã¡ããã·ããšãã«ïŒã¡ã ã«ãâ1HâïŒïŒïŒïŒïŒâã㪠ã¢ãŸãŒã« 25 飜åèèªé žã°ãªã»ãªããå ããŠèš2000mgãšã
ãã 掻æ§æåãNo.60ã¡ãã·ãŠïŒU.S.sieveïŒã®ãµã
ãã«ãããæå°é床ã®å ç±ã«ãã€ãŠäºãèãããŠ
ããã飜åèèªé žã°ãªã»ãªãäžã«æžæ¿ããã次ã
ã§ãã®æ··åç©ãå ¬ç§°å®¹éïŒïœã®åè¬åã«æ³šå ¥ããŠ
æŸå·ããã å®æœäŸ ïŒ çšéïŒmläžã«è¬ç©ïŒmgãå«æããæžæ¿æ¶²ã以äž
ã®åŠãã«èª¿è£œãããæå éïŒæžæ¿æ¶²ïŒmläžïŒ ïŒ(2)âãïŒïŒâããªãžã« ïŒïŒïŒïŒïŒãžãã«ãªãããšã ã«ïŒã¡ãã«ãâ1HïŒ2HïŒ âããã©ãŸãŒã« 50mg ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ ã»ãããªãŠã 50mg ã·ããã 1.25ml å®æ¯éŠé žæº¶æ¶² 0.10ml ãã¬ãŒã㌠é©é çè²æ é©é 粟補氎ãå ããŠèšïŒmlãšããã è¬ç©ãNo.45ã¡ãã·ãŠïŒU.S.siveïŒã®ãµããã«ã
ããã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ã»ãããªãŠã ã
ãã³ã·ããããšæ··åããŠæ»ãããªããŒã¹ãç¶ã«ã
ããå®æ¯éŠé žæº¶æ¶²ããã¬ãŒããŒããã³çè²æãå°
éã®æ°Žã§èããæ¹æããªããå ããã次ãã§ææ
ã®å®¹éã«ãªããŸã§æ°Žãå ããã å®æœäŸ 10 以äžã®æåãå«æããŠããåŽé§å€æº¶æ¶²ã調補ã
ããæå éïŒééïŒ ïŒ ïŒâïŒãžããšãã«ã¡ãã«ïŒâ1H âïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« 0.25 ãšã¿ããŒã« 29.75 ãããã©ã³ã22 70.00 ïŒã¯ãããžãã«ãªãã¡ã¿ã³ïŒ 掻æ§ååç©ããšã¿ããŒã«ãšæ··åãããã®æ··åç©
ããããã©ã³ã22ã®äžéšã«å ããâ30âã«å·åŽã
ãŠå å¡«è£ çœ®ã«ç§»ããææéãã¹ãã³ã¬ã¹éŒè£œã®å®¹
åšã«å ¥ããæ®ãã®ãããã©ã³ãã§åžéããã次ã
ã§ãã«ãâåŒã容åšã«åãä»ããã
ã«ãããªãã«ãªãã¡ãã«ãã¡ããã·ããŸãã¯ãã
ã²ã³ïŒïŒ¥ããã³ïŒ±ã¯åã ç¬ç«ããŠïŒ®ãŸãã¯CHã
è¡šãããã ããããã³ïŒ±ãåæã«ïŒ®ãè¡šãããš
ã¯ãªããïŒ ã§ç€ºãããããªã¢ãŸãŒã«ããã³ããã©ãŸãŒã«åå
ç©ããŸãã¯ãã®å¡©ã«é¢ãããã®ã§ããã åŸæ¥æè¡ ãšã¹ããã²ã³é¡ã¯ã¢ã³ããã²ã³ç³»ã¹ããã€ãé¡
ããåæãããããšã¹ããã²ã³ã®çåæéçšã«ã
ããŠã¯ãè³éŠæåãå¿ é ã®å·¥çšã§ãããäžè¬ã«ã
ãã®ã¢ããã¿ãŒãŒïŒè³éŠæåïŒé µçŽ ãå¹æçã«é»
害ãåŸããªãã°ããšã¹ããã²ã³äŸåæ§çŸæ£ã®æ²»ç
ã«æçšã§ããããšèããããŠããïŒã«ã³ãµãŒã»ãª
ãµãŒãïŒCancer ResearchïŒ42å·»ãå¢åãïŒïŒ
3261SïŒ1982ïŒåç §ïŒã ã¢ããã¿ãŒãŒé»å®³å€ã§æ²»çãåŸããšã¹ããã²ã³
äŸåæ§çŸæ£ã«å¹Ÿã€ãã®ãã®ãããããã®æ§ãªçŸæ£
ã«ã¯ãä¹³ãããåå®®å èçãå€å¢èæ§åµå·£çŸæ£ã
è¯æ§ä¹³æ¿çãããã³åå®®å èããçãå«ãŸããã
æãšã¹ããã²ã³å€ã®ä¹³ããæ²»çã«ãããæçšæ§ã¯
æ¢ã«ç«èšŒãããŠããïŒããªãã€ãã·ãŠã»ãžã€ãŒã
ã«ã»ãªãã»ã«ã³ãµãŒïŒBr.J.CancerïŒ25 270
ïŒ1971ïŒåç §ãïŒïŒã€ã®æ¢ç¥ã®ã¢ããã¿ãŒãŒé»å®³
å€ããã¹ãã©ã¯ãã³ããã³ã¢ããã°ã«ãããã
ã¯ãä¹³ããã®æ²»çã«æå¹ã§ããããšãããã€ãŠã
ãïŒã«ã³ãµãŒã»ãªãµãŒãïŒåäžïŒåç §ïŒã åå®®å èçã¯ãåå®®å èã®ç°åžžãªå¢æ®ãç¹åŸŽãš
ãããåå®®å èã®å¢æ®ã¯ãšã¹ãã©ãžãªãŒã«äŸåæ§
ã§ãããåŸã€ãŠããšã¹ããã²ã³çæé»å®³å€ã«ãã€
ãŠãã®çŸæ£ã®é²è¡ãåæ¢ãããããšãã§ããã¯ã
ã§ããã è¯æ§ä¹³æ¿çã¯ããã°ãã°ç·ç¶å¢èæ§ä¹³æ¿çãšã
åŒã°ããçŸæ£ã§ãããåµå·£ã¹ããã€ããã«ã¢ã³äŸ
åæ§ãšæãããïŒã«ã³ãµãŒïŒCancerïŒ49 2534
ïŒ1982ïŒåç §ïŒããã®çŸæ£ã«å¯ŸããŠã¢ããã¿ãŒãŒé»
害å€ã®äœ¿çšãè©Šã¿ãäŸã¯ãªãããæãšã¹ããã²ã³
é¡ã¯æå¹ã§ãããšæãããïŒãªãã¹ãããªã¯ã¹ã»
ã®ãã³ããžã€ïŒObstet.Gynecol.ïŒ5480ïŒ1979ïŒå
ç §ïŒã å€å¢èæ§åµå·£çŸæ£ã¯ã女æ§ã«ãããäžåŠçã®æ
ãäžè¬çãªåå ã®ïŒã€ã§ããããã®çŸæ£ã®ç å
ã¯ãã¹ããã€ãã®ä»£è¬ç°åžžã«ãããããã該çŸæ£
ã®äž»èŠãªæ²»çå€ã¯æãšã¹ããã²ã³å€ãã¯ããããš
ã³ã§ããïŒã¯ãªãã«ã«ã»ãšã³ãã¯ãªãããžã€
ïŒClin.Endocrinol.ïŒ12 177ïŒ1980ïŒåç §ïŒã çºæã®æ§æããã³ç®ç æ¬çºæã«ãããŠå¥œãŸããååç©ã¯ãåŒäžïŒ(a)
R1ãããã²ã³ãç¹ã«åŒçŽ ãŸãã¯å¡©çŽ ããããã¯
ããªãã«ãªãã¡ãã«ã§ããã(b)ãããšãã«
ïŒR3ããã³R4ã®äž¡æ¹ãæ°ŽçŽ ã§ããïŒãŸãã¯çœ®æã
ãšãã«ãç¹ã«ãR3ãããã²ã³ïŒäžã§ãå¡©çŽ ãŸã
ã¯åŒçŽ ïŒãããã¯ããªãã«ãªãã¡ãã«ã§ããåå
ç©ã§ãããç¹ã«å¥œãŸããã®ã¯ãåŒäžïŒ(a)R1ãã
ã³R2ãå ±ã«å¡©çŽ ãç¹ã«ïŒïŒïŒâãžã¯ããã§ããã
ãé眮æããšãã«ã§ãããããŸãã¯(b)ãã¢ã
眮æããšãã«ãR1ããã³R3ãåã ç¬ç«ããŠå¡©çŽ
ãŸãã¯åŒçŽ ããããŠR2ããã³R4ãæ°ŽçŽ ã§ããå
åç©ã§ããã æã奜ãŸããæ¬çºæååç©ã¯ïŒâããã¹ïŒïŒâ
ã¯ããããšãã«ïŒã¡ãã«ãâ1HâïŒïŒïŒïŒïŒâã
ãªã¢ãŸãŒã«ããã³ïŒâããã¹ïŒïŒâã¯ããããšã
ã«ïŒã¡ãã«ãâ2Hâããã©ãŸãŒã«ããã³ãããã®
è¬åŠçã«èš±å®¹ãåŸãå¡©ã§ããã æ¬æ现æžäžãâããã²ã³âãšããèªå¥ã¯ãåŒçŽ ã
å¡©çŽ ãèçŽ ããã³æ²çŽ ãæå³ãããâããªãžã«â
ãšããèªå¥ã¯ïŒâãïŒâãŸãã¯ç¹ã«ïŒâããªãžã«
ãæå³ããã åœæ¥è ã«ã¯ç解ãããããšã ããäžèšã®åŒã§ç€º
ãããååç©ã«ã¯äžæŽççŽ ååãååšãåŸããæ¬
çºæã¯ç¹å®ã®ç°æ§äœã«éå®ããããã®ã§ã¯æ±ºããŠ
ãªãã該ååç©ã®åã ã®ãšãã³ããªããŒããã³ã©
ã»ãäœãå å«ãããã®ã§ããã ãŸããããã³ïŒ±ã®å ãäžæ¹ãã§ä»æ¹ãCH
ã®ãšãã¯ãäžèšã®åŒã§ç€ºãããååç©ã¯ïŒâãŸã
ã¯ïŒâ眮æããã©ãŸãŒã«ãšãªãããããã®ïŒã€ã®
åã®ããã©ãŸãŒã«ååç©ã¯å¥ã ã®é ã§ç¹èš±è«æ±ã
ããŠãããã補é æ¹æ³ã«ãã€ãŠã¯ããããã¯äžç·
ã«çæãããåŸã€ãŠãæ¬çºæã¯ïŒâããã³ïŒâ眮
æããã©ãŸãŒã«ã®åã ã䞊ã³ã«ãããã®æ··åç©ã
å å«ãããã®ã§ãããæ¬æ现æžäžãäžèšã®æ··åç©
ããïŒ(2)â眮æããã©ãŸãŒã«ãšè¡šãã åèšã®åŒã§ç€ºãããå¡©åºã®è¬åŠçã«èš±å®¹ãåŸã
é žä»å å¡©ã¯ãä»å å¡©ã圢æããã®ã«å åãªé žæ§åºŠ
ã®é žãçšããŠåŸãããšãã§ããããã®æ§ãªé žã«
ã¯ãå¡©é žãèåæ°ŽçŽ é žãæ²åæ°ŽçŽ é žãç¡«é žããã
é žãä¿®é žãã¡ã¿ã³ã¹ã«ãã³é žããã³ãŒã³ã¹ã«ãã³
é žãïœâãã«ãšã³ã¹ã«ãã³é žããã³ãã¬ã€ã³é žç
ã®ç¡æ©ããã³ææ©é žãå«ãŸãããå¡©ã®åœ¢æã«å¥œãŸ
ããã®ã¯ç¡æ©é žãç¹ã«å¡©é žã§ããã åŒã®ååç©ã®è£œé æ¹æ³ æ¬çºæååç©ã¯æ°çš®é¡ã®æ¹æ³ã®å ãä»»æã®æ¹æ³
ã§è£œé ããããšãã§ãããæ¬çºæååç©ã®å¥œãŸã
ã補é æ¹æ³ã¯ã以äžã®åå¿åŒïŒ ãåŒäžãã¯ããã²ã³ïŒå¥œãŸããã¯å¡©çŽ ãŸãã¯è
çŽ ïŒãããã¯ããããã·ãè¡šãã ã§ç€ºããããéåžžãååç©ãšãšããã¢ã«ã«ãª
éå±ã®æ°ŽçŽ åç©ãæ°Žé žåç©ãã¢ã«ã³ãã·ãåå
ç©ããŸãã¯çé žå¡©ã®åŠãå¡©åºã®ååšäžã奜ãŸãã
ã¯ãžãªããµã³ããŸãã¯ãžã¡ãã«ãã«ã ã¢ããã®åŠ
ããžã¢ã«ãã«ãã«ã ã¢ããã®æ§ãªé«æ²žç¹ã®éâå
å¿æ§æº¶åªäžã§åå¿ããããäžè¬ã«ãã¢ãŸãŒã«èªå°
äœããéåžžãå ããªéå°éããïŒåéå°éã®ç¯
å²å ã§ãéå°ã«çšãããæ®éãåå¿ã¯ãäžæŽ»æ§é°
å²æ°äžãçŽ20âããåå¿æ··åç©ã®æ²žç¹ãŸã§ã®æž©åºŠ
ç¯å²ã§è¡ããæ°ŽçŽ åãããªãŠã ãšãžã¡ãã«ãã«ã
ã¢ããã䜿çšãã枩床çŽ80°ã100âã®å¥œãŸããå
å¿æ¡ä»¶ã®äžã§ã¯ãåå¿ã¯ãéåžžãçŽïŒã24æéã®
å ã«çµäºãããäžéäœããã³ã¯ãåžè²©åãå ¥
æãåŸãããæç®ã«èšèŒãããŠããããããã¯åœ
æ¥è åšç¥ã®æ¹æ³ã§å®¹æã«è£œé ããããšãã§ããã 以äžã«å®æœäŸãæããæ¬çºæãæŽã«è©³ãã説æ
ããããããã®å®æœäŸã¯åãªãäŸç€ºã«ããããåŠ
äœãªãæå³ã«ãããŠãæ¬çºæã®ç¯å²ãå¶éããã
ã®ã§ã¯ãªãã å®æœäŸ ïŒ ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ
2Hâããã©ãŸãŒã«  ïŒïŒ4â²âãžã¯ãããã³ãºãããªã«ã»ã¯ããªã
ã®è£œé ïŒïŒ4â²âãžã¯ãããã³ãºããããŒã«75ïœã«å¡©
åããªãã«42ïœãåŸã ã«å ãããæ·»å çµäºåŸã
åå¿æ··åç©ãèžæ°æµŽäžã§ïŒæéå ç±ãããéå°
éã®å¡©åããªãã«ãæžå§äžã«é€å»ãããåå¡©å
ççŽ 100mlãå ãã溶åªãçå»ããããã®åå¡©
åççŽ ã«ããåŠçãç¹°è¿ããŠè¡ã€ãåŸãæ²¹ç¶ã®
æ®çç©ãç³æ²¹ãšãŒãã«ããçµæ¶åãããå¯é¡ã®
äžéäœ65.3ïœãåŸããmpïŒ63âã  ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ
2Hâããã©ãŸãŒã«ã®è£œé ããã©ãŸãŒã«3.12ïœãçé žã«ãªãŠã 26.2ïœã
ãã³äžã§åŸãïŒïŒ4â²âãžã¯ãããã³ãºãããª
ã«ã»ã¯ããªã10ïœã®æ··åç©ãçªçŽ é°å²æ°äžããž
ã¡ãã«ãã«ã ã¢ãã150mläžã§85ã90âã«ãã
ãŠ2.5æéãæŽã«60ã65âã«ãããŠäžå€å ç±ã
ãããã®åå¿æ··åç©ãå¡©åãããªãŠã 飜å溶液
ïŒäžã«æ³šå ããåŸãé ¢é žãšãã«200mlã§ïŒå
æœåºãããææ©æœåºæ¶²ãåãããŠå¡©åãããªãŠ
ã 飜å溶液ã§ïŒåæŽæµããç¡«é žãã°ãã·ãŠã ã§
也ç¥ããåŸãèžçºä¹ŸåºããŠæ·¡é»è²ã®æ²¹ç¶ç²çæ
ç©12.1ïœãåŸãããã®æ®çç©ãé«é液äœã¯ãã
ãã°ã©ãã€ãŒã§ç²Ÿè£œãããã¡ã¿ããŒã«ããåçµ
æ¶ããïŒâããã©ãŸãŒã«èªå°äœã®çœè²çµæ¶1.1
ïœãäžæ¬¡çæç©ãšããŠååãããmpïŒ91ã92
âããã®çæç©ããã¹ã¹ãã¯ãã«åæã«ããã
劥åœãªååéãæããŠããããšïŒM+ïŒ305ïŒã
確èªãããšå ±ã«ã13Cããã³1HNMR NOEå®éš
ã«ããããã®äžæ¬¡çæç©ããïŒâããã¹ïŒïŒâ
ã¯ããããšãã«ïŒã¡ãã«ãâ2Hâããã©ãŸãŒã«
ã§ããããšã確èªããã ïŒC14H10Cl2N4ïŒå çŽ åæ    èšç®å€ïŒ55.10 3.30 18.36 å®æž¬å€ïŒ55.05 3.45 18.18 å®æœäŸ ïŒ ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ
1HâïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« å®æœäŸ1Bã®äžè¬çãªæ¹æ³ã«åŸããïŒïŒïŒïŒïŒ
âããªã¢ãŸãŒã«5.0ïœã®ãžã¡ãã«ãã«ã ã¢ãã100
mläžæº¶æ¶²ãããŸãæ°ŽçŽ åãããªãŠã ïŒ60ïŒ é±æ²¹äž
溶液ãšããŠïŒ1.44ïœã次ãã§ïŒïŒ4â²âãžã¯ããã
ã³ãºãããªã«ã»ã¯ããªã5.0ïœã§åŠçããããã®
åå¿æ··åç©ãçŽ25âã§äžå€æ¹æããåŸãèžæ°æµŽäž
ã§äžå€å ç±ãããäžé£ã®å®éšçµäºåŸãæ®çç©ãã¯
ãããã°ã©ãã€ãŒã«ããããšãããç®çç©è³ªã§ãª
ãïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ
2HâïŒïŒïŒïŒïŒâããªã¢ãŸãŒã«2.4ïœãšãç®çç©
質ã§ããè¡šé¡ã®ååç©3.1ïœãšãåŸããmpïŒ124
ã125âã ïŒC15H11Cl2N3ïŒå çŽ åæ    èšç®å€ïŒ59.23 3.65 13.81 å®æž¬å€ïŒ59.45 3.86 13.81 æ¬çºæååç©çŸ€ã¯ãã¢ããã¿ãŒãŒé µçŽ é»å®³æŽ»æ§
ãæããŠãããåŸã€ãŠãåºä¹³é¡åç©ã«ãããä¹³ã
ãçã®ãšã¹ããã²ã³äŸåæ§çŸæ£ã«å¯Ÿããäºé²ç
ãªããŸãã¯æ²»çãç®çãšããåŠçã«äœ¿çšã§ããã
æ¬çºæååç©ã®ã¢ããã¿ãŒãŒé»å®³æŽ»æ§ãã
Brodieãã®ãåé¢ããã©ããã®åµå·£ãã¯ããŸãŒ
ã ãçšããæ¹æ³ïŒãžã€ãŒãã«ã»ãªãã»ã¹ããã€
ãã»ãã€ãªã±ãã¹ããªã€ïŒJ.Steroid Biochem.ïŒ
ïŒ 787ïŒ1976ïŒïŒã®æ¹è¯æ³ã«ãã蚌æããããã®
å®éšã·ã¹ãã ã«ãããŠã¯ãåŠéŠ¬ã®è¡æž ãŽãããã
ãã³ã§åŠçããã©ããããåµå·£ãã¯ããŸãŒã ãå
é¢ããã0.1ÎŒïœã®ïŒâã¢ã³ããã¹ãã³âïŒïŒ17â
ãžãªã³ã100000dpmã®ïŒïŒïŒïŒ»3Hâã¢ã³ããã¹
ãã³ãžãªã³ãäžèšã®ãã¯ããŸãŒã ããã³
NADPHçæç³»ãå«æããåå¿å®¹åšïŒãã€ã¢ã«ïŒ
ã«è¢«æ€ååç©ãå ãããè©Šéšãããã®é»å®³å€ã®æ¿
床ç¯å²ã¯0.005ã10ÎŒïœã§ããããã®æž¬å®æ³ã«ãã
ã°ãã¢ã³ããã¹ãã³ãžãªã³ã®è³éŠæåã«ãã€ãŠ
3HâH2Oãçæããã®ã§ãããããè©Šæãã¯
ãããã«ã ã§æœåºããããšã«ãã€ãŠåé¢ããåŸã
ããæ°Žå±€ã掻æ§çåŠçããŠéé¢ã®ã¹ããã€ããé€
ããè©Šæã液äœã·ã³ãã¬ãŒã·ãšã³åå åšã«å ¥ããŠ
èšæ°ãããã®çµæããé»å®³å€ãå ããã«ã€ã³ããŠ
ããŒãããŠåŸãå¯Ÿç §è©Šæã«ãããçµæãšæ¯èŒãã
ããšã«ãããé»å®³çïŒïŒ ïŒãæ±ãããå¹åã¯ãåº
質ïŒã¢ã³ããã¹ãã³ãžãªã³ïŒã®æ¿åºŠã0.1ÎŒïœã®å Ž
åã«ãããŠãé µçŽ æŽ»æ§ã50ïŒ é»å®³ããã®ã«å¿ èŠãª
é»å®³å€ã®æ¿åºŠïŒÎŒïœïŒã«åºã¥ããŠè¡šãã
ïŒEC50ïŒãåèšã®åŒã§ç€ºãããããã€ãã®ååç©
ã®EC50å€ãè¡šïŒã«ç€ºãã è¡šïŒ ã©ããåµå·£ãã¯ããŸãŒã ã¢ãã»ã€ã«ãããã¢ãã
ã¿ãŒãŒé»å®³äœçš â»è¢«æ€ååç© EC50 ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ1H
âïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« ïŒ0.05 ïŒâããã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ãâ2H
âããã©ãŸãŒã« 0.15 â» åºè³ªæ¿åºŠ0.1ÎŒïœã®å Žåã«ã¢ããã¿ãŒãŒæŽ»æ§
ã50ïŒ é»å®³ããã®ã«å¿ èŠãªè¢«æ€ååç©ã®æ¿åºŠ
ïŒåäœÎŒïœïŒã æ¬çºæååç©ã¯ãçµå£ãç®äžãçèå ãéè
å ãçµç®ããã³çµçŽè žãå«ãçš®ã ã®çµè·¯ã§æäžã
ãããšãã§ãããæ¬çºæååç©ã¯ãäžè¬ã«å»è¬çµ
æç©ã®åœ¢ã§çšããããããããã®çµæç©ã¯è£œè¬æ¥
è åšç¥ã®æ¹æ³ã§è£œé ãããå°ãªããšãïŒåã®åèš
ã®åŒã§ç€ºããã掻æ§ååç©ãå«æããŠããã åŸã€ãŠæ¬çºæã¯ã掻æ§æåã§ããåèšåŒã®åå
ç©ãšãè¬åŠçã«èš±å®¹ãåŸãåŠäœãšãå«æããå»è¬
çµæç©ãå å«ãããã®ã§ããããã®çµæç©ã調補
ããã«ã¯ãéåžžã掻æ§æåãåŠäœãšæ··åãããåŠ
äœã§åžéãããããŸãã¯ãã«ãã»ã«ããµã·ãšãçŽ
çã®å®¹åšã®åœ¢ç¶ãæããä¿æäœå ã«å°å ¥ããã åŠäœãåžéå€ã§ããå Žåãããã¯æŽ»æ§ç©è³ªã«å¯Ÿ
ãã賊圢è¬ãè£åœ¢è¬ãŸãã¯åªè³ªãšããŠäœçšããåº
åç©è³ªãååºåç©è³ªãŸãã¯æ¶²äœç©è³ªã§ãããäŸã
ã°ãæ¬çºæã®çµæç©ã¯ãé å€ãäžžå€ãç²å€ãããŒ
ã³ãžããµã·ãšå€ãã«ã·ãšå€ããšãªãã·ã«å€ãä¹³
å€ã液å€ãã·ãããå€ãæžæ¿å€ãåŽé§å€ïŒåºäœãš
ããŠããŸãã¯æ¶²äœåªè³ªã«å ¥ããŠïŒãè»èïŒäŸãã°
掻æ§ååç©ãæé«10ééïŒ å«æãããã®ïŒããŒã©
ãã³è»ã«ãã»ã«ããã³ãŒã©ãã³ç¡¬ã«ãã»ã«ãå
è¬ãæ» è泚å°çšæ¶²äžŠã³ã«æ» èå è£ ç²å€çã®å€åœ¢ã
ãšãåŸãã é©åœãªåŠäœãè£åœ¢è¬ãŸãã¯åžéå€ã«ã¯ãäŸã
ã°ãä¹³ç³ãããã¹ãããŒã¹ãã·ãŠã¯ããŒã¹ããœã«
ãããŒã«ããã³ãããŒã«ããã³ãã³ãã¢ã«ã·ã¢ãŽ
ã ããªã³é žã«ã«ã·ãŠã ãã¢ã«ã®ããŒãé¡ãã±ã€é ž
ã«ã«ã·ãŠã ã埮çµæ¶ã»ã«ããŒã¹ãããªããã«ãã
ãªãã³ãã»ã«ããŒã¹ããã©ã¬ã«ã³ãããŒã©ãã³ã
ã·ããããã¡ãã«ã»ã«ããŒã¹ããªãã·å®æ¯éŠé žã¡
ãã«ããªãã·å®æ¯éŠé žãããã«ãã¿ã«ã¯ãã¹ãã¢
ãªã³é žãã°ãã·ãŠã ãæ°Žããã³é±æ²¹ãå«ãŸããã
ãŸããæ¬çºæã®å»è¬è£œå€ã«ã¯æ»æ²¢å€ã湿最å€ãä¹³
åå€ããã³æžæ¿å€ãé²è å€ãçå³æãŸãã¯ãã¬ãŒ
ããŒçãæ·»å ããŠããããæ¬çºæã®çµæç©ã¯ãåœ
æ¥è åšç¥ã®æ¹æ³ãçšããŠãæ£è ã«æäžããåŸã«æŽ»
æ§æåãè¿ éã«ãæç¶çã«ãŸãã¯é 延ããŠæŸåºã
ãæ§ã«è£œå€åããããšãã§ããã çµå£æäžã®ç®çã«ã¯ãæ¬çºæååãåŠäœããã³
åžéå€ãšæ··åããŠé å€ã«æé ãããããŒã©ãã³ã«
ãã»ã«ã«å å¡«ããããšãã§ããããããã¯ãŸãã
ãã®æ··åç©ã10ïŒ ãããŠç³æ°Žæº¶æ¶²ãç匵æ§é£å¡©æ°Ž
ããã³æ» èæ°Žçã®æ¶²äœã«æº¶è§£ããéèå æäžããŸ
ãã¯æ³šå°ããŠãããããã®æ§ãªæ§çµµããææã«ã
ãåçµä¹Ÿç¥ããŠæ» èã¢ã³ãã«ã«ä¿åããŠãããçš
ææ» èæ°Žãå ããŠçèå 泚å°ã®ããã®æ³šå°æ¶²ã«å
調補ãåŸãããã«ããŠãããã ãããã®çµæç©ã¯ãæäžå€åœ¢äžã«æŽ»æ§æåãçŽ
ïŒãçŽ500mgãããäžè¬çã«ã¯çŽïŒãçŽ300mgå«æ
ãããæ§ã«ãæäžåäœå€åœ¢ã«è£œå€åããããšã奜
ãŸãããâæäžåäœå€åœ¢âãšããèªå¥ã¯ããã察
象ãŸãã¯ä»ã®åºä¹³åç©ã«å¯ŸããŠé©åãªåäžã®çšé
ãå«ããç©ççã«ç¬ç«ããäžã€ã®æäžåäœã§ãã€
ãŠãææã®æ²»çå¹æãçŸããããšãäºæ³ãããèš
ç®éã®æŽ»æ§æåãšãææã®è£œè¬çšæ äœãšãå«æã
ããã®ãæãã 掻æ§ååç©ã¯åºç¯ãªçšéåã§æå¹ã§ãããäŸã
ã°ïŒæ¥åœããã®æäžéã¯éåžžçŽ0.05ãçŽ300mgïŒ
Kgã®ç¯å²å ãšãªãããããæ人ã«å¯Ÿããæ²»çæã«
ã¯ãçŽ0.1ãçŽ50mgïŒKgãïŒåã§ãŸãã¯åå²æäž
ãããšãããããããªãããå®éã®æäžéã¯ãæ²»
çæ¡ä»¶ãéžã°ããæäžååç©ãåã ã®æ£è ã®å¹Ž
什ãäœéããã³å¿çæ§ãçç¶ã®é節床ã䞊ã³ã«éž
æãããæäžçµè·¯çãå«ãé¢é£äºé ã«ç §ãããŠå»
åž«ã決å®ããã®ã§ãäžèšã®çšéåã決ããŠæ¬çºæ
ã®ç¯å²ãéå®ãããã®ã§ãªããšããããšã¯ç解ã
ããã§ãããã 以äžã«è£œå€ã«é¢ããå®æœäŸãæããæ¬çºæã®å®
æœæ æ§ãæŽã«è©³ãã説æããããããã®è£œå€äŸã¯
åãªãäŸç€ºã«ãããããããªãæå³ã«ãããŠãæ¬
çºæã®ç¯å²ãå¶éãããã®ã§ã¯ãªãããããã®è£œ
å€äžã«ã¯ãåèšã®åŒã§ç€ºãããæ¬çºæã®å»è¬åå
ç©ãã掻æ§æåãšããŠå«æãããŠããã å®æœäŸ ïŒ ä»¥äžã®æåã§ãŒã©ãã³ç¡¬ã«ãã»ã«ã調補ãããæå éïŒmgïŒã«ãã»ã«ïŒ ïŒâããã¹ïŒïŒâãã«ãªãã ãšãã«ïŒã¡ãã«ãâ1Hâ ïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« 250 也ç¥ãã³ãã³ 200 ã¹ãã¢ãªã³é žãã°ãã·ãŠã 10 èš 460 äžèšæåãæ··åãããŒã©ãã³ç¡¬ã«ãã»ã«ã«å 容
é460mgãšããŠå å¡«ããã å®æœäŸ ïŒ è¬ç©20mgãå«æããã«ãã»ã«å€ã以äžã®åŠãã«
ããŠèª¿è£œãããæå éïŒmgïŒã«ãã»ã«ïŒ ïŒ(2)âãïŒïŒâã¯ããã ãšãã«ïŒïŒïŒâãã«ãªãããš ãã«ïŒã¡ãã«ãâ1HïŒ2H ïŒâããã©ãŸãŒã« 20 ãã³ãã³ 89 埮çµæ¶ã»ã«ããŒã¹ 89 ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒ èš 200 掻æ§æåãã»ã«ããŒã¹ããã³ãã³ããã³ã¹ãã¢
ãªã³é žãã°ãã·ãŠã ãæ··åããNo.45ã¡ãã·ãŠã®ãµ
ããïŒU.S.sieveïŒã«ããã容é200mgã§ãŒã©ãã³
硬ã«ãã»ã«ã«å å¡«ããã å®æœäŸ ïŒ æŽ»æ§æå100mgãå«æããã«ãã»ã«å€ã以äžã®
åŠã調補ãããæå éã«ãã»ã« ïŒâãïŒïŒâããªãã«ãªã ã¡ãã«ããšãã«ïŒïŒïŒâããªãž ã«ïŒã¡ãã«ãâ1HâïŒïŒ ïŒïŒïŒâããªã¢ãŸãŒã« 100mg ããªãªãã·ãšãã¬ã³ãœã« ãã¿ã³ã»ã¢ããªã¬ãšãŒã 50mcg ãã³ãã³æ« 250mg äžèšæåãè¯ãæ··åãã空ã®ãŒã©ãã³ã«ãã»ã«
ã«å å¡«ããã å®æœäŸ ïŒ æŽ»æ§æå10mgãå«æããé å€ã以äžã®æ¹æ³ã§èª¿
補ãããæå éïŒmgïŒé ïŒ ïŒ(2)âãïŒïŒïŒïŒâãžã¯ãã ããšãã«ïŒïŒïŒâã¯ããããšã ã«ïŒã¡ãã«ãâ1HïŒ2HïŒâã ãã©ãŸãŒã« 10 ãã³ãã³ 45 埮çµæ¶ã»ã«ããŒã¹ 35 ããªããã«ãããªãã³ ïŒ10ïŒ æ°Žæº¶æ¶²ãšããŠïŒ ïŒ ã«ã«ããã·ã¡ãã«ã»ãã³ãã³ ã»ãããªãŠã 4.5 ã¹ãã¢ãªã³é žãã°ãã·ãŠã 0.5 ã¿ã«ã¯ ïŒ èš 100 掻æ§æåããã³ãã³ããã³ã»ã«ããŒã¹ãNo.45ã¡
ãã·ãŠïŒU.S.sieveãã¢ã¡ãªã«æšæºãµããïŒã®ãµ
ããã«ãããŠããæ··åããŠãããåŸãããç²æ«ã
ããªããã«ãããªãã³æº¶æ¶²ãšæ··åããåŸãNo.14ã¡
ãã·ãŠïŒU.S.sieveïŒã®ãµããã«ãããããã®æ§
ã«ããŠåŸãããé¡ç²ã50ã60âã§ä¹Ÿç¥ããNo.18ã¡
ãã·ãŠïŒU.S.sieveïŒã®ãµããã«ãããã次ãã§ã
äºãNo.60ã¡ãã·ãŠïŒU.S.sieveïŒã®ãµããã«éã
ãŠãããã«ã«ããã·ã¡ãã«ãã³ãã³ã»ãããªãŠ
ã ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ããã³ã¿ã«ã¯ãã
ã®é¡ç²ã«å ããæ··åããåŸãæé æ©ã«å ¥ããæé
ããå100mgã®é å€ãåŸãã å®æœäŸ ïŒ ä»¥äžã®æåã§é å€ã調補ãããæå éïŒmgïŒé ïŒ ïŒâãïŒâïŒïŒâã¯ããããšã ã«ïŒâïŒâããšãã«ãšãã«ãâ 1HâïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« 250 埮çµæ¶ã»ã«ããŒã¹ 400 溶èäºé žåã±ã€çŽ 10 ã¹ãã¢ãªã³é ž ïŒ èš 665 äžèšæåãæ··åããå665mgã®é å€ã«æé ããã å®æœäŸ ïŒ æŽ»æ§æå25mgãå«æããåè¬ã以äžã®åŠãã«èª¿
補ããã éïŒmgïŒåè¬ïŒ ïŒâãïŒïŒâã¡ãã«ããšãã«ïŒ ïŒïŒâã¡ããã·ããšãã«ïŒã¡ã ã«ãâ1HâïŒïŒïŒïŒïŒâã㪠ã¢ãŸãŒã« 25 飜åèèªé žã°ãªã»ãªããå ããŠèš2000mgãšã
ãã 掻æ§æåãNo.60ã¡ãã·ãŠïŒU.S.sieveïŒã®ãµã
ãã«ãããæå°é床ã®å ç±ã«ãã€ãŠäºãèãããŠ
ããã飜åèèªé žã°ãªã»ãªãäžã«æžæ¿ããã次ã
ã§ãã®æ··åç©ãå ¬ç§°å®¹éïŒïœã®åè¬åã«æ³šå ¥ããŠ
æŸå·ããã å®æœäŸ ïŒ çšéïŒmläžã«è¬ç©ïŒmgãå«æããæžæ¿æ¶²ã以äž
ã®åŠãã«èª¿è£œãããæå éïŒæžæ¿æ¶²ïŒmläžïŒ ïŒ(2)âãïŒïŒâããªãžã« ïŒïŒïŒïŒïŒãžãã«ãªãããšã ã«ïŒã¡ãã«ãâ1HïŒ2HïŒ âããã©ãŸãŒã« 50mg ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ ã»ãããªãŠã 50mg ã·ããã 1.25ml å®æ¯éŠé žæº¶æ¶² 0.10ml ãã¬ãŒã㌠é©é çè²æ é©é 粟補氎ãå ããŠèšïŒmlãšããã è¬ç©ãNo.45ã¡ãã·ãŠïŒU.S.siveïŒã®ãµããã«ã
ããã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ã»ãããªãŠã ã
ãã³ã·ããããšæ··åããŠæ»ãããªããŒã¹ãç¶ã«ã
ããå®æ¯éŠé žæº¶æ¶²ããã¬ãŒããŒããã³çè²æãå°
éã®æ°Žã§èããæ¹æããªããå ããã次ãã§ææ
ã®å®¹éã«ãªããŸã§æ°Žãå ããã å®æœäŸ 10 以äžã®æåãå«æããŠããåŽé§å€æº¶æ¶²ã調補ã
ããæå éïŒééïŒ ïŒ ïŒâïŒãžããšãã«ã¡ãã«ïŒâ1H âïŒïŒïŒïŒïŒâããªã¢ãŸãŒã« 0.25 ãšã¿ããŒã« 29.75 ãããã©ã³ã22 70.00 ïŒã¯ãããžãã«ãªãã¡ã¿ã³ïŒ 掻æ§ååç©ããšã¿ããŒã«ãšæ··åãããã®æ··åç©
ããããã©ã³ã22ã®äžéšã«å ããâ30âã«å·åŽã
ãŠå å¡«è£ çœ®ã«ç§»ããææéãã¹ãã³ã¬ã¹éŒè£œã®å®¹
åšã«å ¥ããæ®ãã®ãããã©ã³ãã§åžéããã次ã
ã§ãã«ãâåŒã容åšã«åãä»ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒïŒ ïŒåŒäžãã¯ãåŒã R1ãR2ãR3ããã³R4ã¯åã ç¬ç«ããŠæ°ŽçŽ ãã¡ã
ã«ãããªãã«ãªãã¡ãã«ãã¡ããã·ããŸãã¯ãã
ã²ã³ïŒïŒ¥ããã³ïŒ±ã¯åã ç¬ç«ããŠïŒ®ãŸãã¯CHã
è¡šãããã ããããã³ïŒ±ãåæã«ïŒ®ãè¡šãããš
ã¯ãªããïŒ ã§ç€ºãããååç©ãŸãã¯ãã®å¡©ã ïŒ R1ããã³R3ãåã ç¬ç«ããŠå¡©çŽ ãŸãã¯åŒçŽ
ã§ãã第ïŒé ã«èšèŒã®ååç©ã ïŒ ïŒâãã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ïŒœâ
1HâïŒïŒïŒïŒïŒâããªã¢ãŸãŒã«ãŸãã¯ãã®å¡©ã§
ãã第ïŒé ã«èšèŒã®ååç©ã ïŒ ïŒâãã¹ïŒïŒâã¯ããããšãã«ïŒã¡ãã«ïŒœâ
2Hâããã©ãŸãŒã«ãŸãã¯ãã®å¡©ã§ãã第ïŒé ã«
èšèŒã®ååç©ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/621,582 US4801594A (en) | 1984-06-18 | 1984-06-18 | Aromatase inhibitors |
| US621582 | 1984-06-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6112676A JPS6112676A (ja) | 1986-01-21 |
| JPH0548228B2 true JPH0548228B2 (ja) | 1993-07-20 |
Family
ID=24490764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60135224A Granted JPS6112676A (ja) | 1984-06-18 | 1985-06-18 | ã¢ããã¿ãŒãŒé»å®³å€ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4801594A (ja) |
| EP (1) | EP0165778B1 (ja) |
| JP (1) | JPS6112676A (ja) |
| AT (1) | ATE40822T1 (ja) |
| CA (1) | CA1270835A (ja) |
| DE (1) | DE3568275D1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112845A (en) * | 1986-03-07 | 1992-05-12 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| US5352795A (en) * | 1986-03-07 | 1994-10-04 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| US4978672A (en) * | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| US4937250A (en) * | 1988-03-07 | 1990-06-26 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| US4749713A (en) * | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| NZ224714A (en) * | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
| GB8714013D0 (en) * | 1987-06-16 | 1987-07-22 | Ici Plc | (substituted-aralkyl)heterocyclic compounds |
| GB8716651D0 (en) * | 1987-07-15 | 1987-08-19 | Ici Plc | 2-propanol derivatives |
| GB8818561D0 (en) * | 1988-08-04 | 1988-09-07 | Ici Plc | Diphenylethane derivatives |
| IE892812L (en) * | 1988-09-12 | 1990-03-12 | Brendan Coleman | Tricyclic aromatase inhibitors |
| ES2084687T3 (es) * | 1989-07-14 | 1996-05-16 | Ciba Geigy Ag | Benzonitrilos substituidos. |
| GB9002375D0 (en) * | 1990-02-02 | 1990-04-04 | Pfizer Ltd | Triazole antifungal agents |
| JPH07247274A (ja) * | 1994-03-10 | 1995-09-26 | Wakamoto Pharmaceut Co Ltd | ããã«é ž ããã©ãŸãªã«ãã§ãã«ãšã¹ãã«èªå°äœãããããæå¹æåãšããŠå«æãããšã©ã¹ã¿ãŒãŒé»å®³å€åã³èºé害治çå€ |
| EP0765857B1 (en) * | 1994-06-13 | 1999-12-08 | Mitsubishi Rayon Co., Ltd. | Process for producing optically active alpha-substituted carboxylic acid derivatives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2407305C2 (de) * | 1974-02-15 | 1984-06-28 | Bayer Ag, 5090 Leverkusen | Triphenyl-1,2,3-triazol-1-yl-methane, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide |
| IL50699A0 (en) * | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| US4094881A (en) * | 1976-03-10 | 1978-06-13 | Smithkline Corporation | Process for preparing triazolethiols |
| GB1511195A (en) * | 1976-10-18 | 1978-05-17 | Ici America Inc | Triazole derivatives |
| US4227004A (en) * | 1979-01-02 | 1980-10-07 | Ici Americas Inc. | Synthesis of substituted 1-aralkyl-1H-v-triazoles |
-
1984
- 1984-06-18 US US06/621,582 patent/US4801594A/en not_active Expired - Fee Related
-
1985
- 1985-06-11 CA CA000483666A patent/CA1270835A/en not_active Expired - Lifetime
- 1985-06-14 AT AT85304233T patent/ATE40822T1/de not_active IP Right Cessation
- 1985-06-14 DE DE8585304233T patent/DE3568275D1/de not_active Expired
- 1985-06-14 EP EP85304233A patent/EP0165778B1/en not_active Expired
- 1985-06-18 JP JP60135224A patent/JPS6112676A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US4801594A (en) | 1989-01-31 |
| EP0165778B1 (en) | 1989-02-15 |
| EP0165778A1 (en) | 1985-12-27 |
| CA1270835A (en) | 1990-06-26 |
| JPS6112676A (ja) | 1986-01-21 |
| ATE40822T1 (de) | 1989-03-15 |
| DE3568275D1 (en) | 1989-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU679119B2 (en) | Azole derivative and pharmaceutical composition thereof | |
| JPH0548228B2 (ja) | ||
| JPS6133175A (ja) | ã¢ããã¿âãŒé»å®³æŽ»æ§ãæããïŒïŒïŒïŒâ眮æã€ãããŸâã«é¡ | |
| US4602025A (en) | Aromatase inhibitors | |
| EP0054417A1 (en) | Indole thromboxane synthetase inhibitors, processes for their preparation, and pharmaceutical compositions containing them | |
| CZ283043B6 (cs) | Nové slouÄeniny inhibujÃcà selektivnÄ aromatázu, způsob jejich pÅÃpravy a jejich pouÅŸità k pÅÃpravÄ farmaceutického prostÅedku | |
| US4609666A (en) | Aromatase inhibiting derivatives of α,α-bis(4-halophenyl)methyltetrazoles and triazoles | |
| JP3133432B2 (ja) | ããçŽ ååç© | |
| US4659730A (en) | Aromatase inhibiting imidazole derivatives | |
| JP3207417B2 (ja) | ã·ã¯ãã¢ã«ãã¬ã³ã¢ãŸãŒã«ããã®è£œé ããããæãã補å€äžŠã³ã«å»è¬åã®è£œé ã®ããã®ãã®äœ¿çš | |
| US4845227A (en) | Aromatase inhibitors from azoles | |
| JPH0521893B2 (ja) | ||
| US4735960A (en) | Aromatase inhibitors | |
| EP0571267B1 (en) | Use of azole derivatives for the preparation of drugs useful for inhibiting the aromatase and treating of estrogen-dependent diseases | |
| US5206256A (en) | Naphthalene derivatives | |
| US4560695A (en) | Isoxazolyl and isothiazolyl aromatase inhibitors | |
| EP0755931A1 (en) | Dihydropyridine and pyridine derivatives and process for their preparation | |
| EP0168965B1 (en) | 4(5)-substituted imidazoles | |
| US4661508A (en) | Aromatase inhibiting α,α-diphenyl-4(5)imidazole-methanes or -ethanes | |
| JPS6117514A (ja) | ã¢ããã¿ãŒãŒé»å®³äœçšãæããïœâ眮æã€ãããŸãŒã«èªå°äœ | |
| HU197729B (en) | Process for producing triazol- and imidazol derivatives and pharmaceutical compositions containing them | |
| JPH04230668A (ja) | ã¢ããã¿ãŒãŒé»å®³äœçšãæããïŒïŒïŒïŒâã€ãããŸãŒã«é¡ |